TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20113458

Group type: EXPERIMENTAL
Intervention: T-SPOT.TB test
Number of subjects: 209

Group type: COMPARATOR
Intervention: TST >= 5 mm
Number of subjects: 209

Group type: COMPARATOR
Intervention: TST >= 10 mm
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Indeterminate T-SPOT.TB test
Number of subjects: 209

Group type: COMPARATOR
Intervention: T-SPOT.TB test vs TST
Number of subjects: 209

Group type: COMPARATOR
Intervention: Induration size of TST
Number of subjects: 209

Group type: COMPARATOR
Intervention: Clinical risk for LTBI
Number of subjects: 209
Study: 20117459

Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 14
Study: 20119473

Group type: EXPERIMENTAL
Intervention: Point of care (POC) urine drug testing
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Liquid chromatography tandem mass spectroscopy (LC/MS/MS)
Number of subjects: 1000
Study: 20121884

Group type: EXPERIMENTAL
Intervention: APOE epsilon4 and ACE D alleles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Severe hypoglycaemic events or high HbA(1c)
Number of subjects: 0
Study: 20124123

Group type: EXPERIMENTAL
Intervention: Quitting smoking
Number of subjects: 18809

Group type: EXPERIMENTAL
Intervention: Adherence to diet and exercise
Number of subjects: 18809

Group type: COMPARATOR
Intervention: Persistent smoking and nonadherence to diet and exercise
Number of subjects: 18809
Study: 20124511

Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide (50 mg/kg/d on days 3 and 4 after transplantation)
Number of subjects: 117
Study: 20124586

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES) - 'off-label' use
Number of subjects: 2067

Group type: COMPARATOR
Intervention: Sirolimus-eluting stents (SES) - 'on-label' use
Number of subjects: 2067

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES) - in diabetics
Number of subjects: 2067
Study: 20126394

Group type: EXPERIMENTAL
Intervention: DNA/rAd5 prime-boost regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: DNA or rAd5 vaccine alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rAd5 boosting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vaccine-elicited CD4(+) and CD8(+) T-cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epitopes in Gag and Env
Number of subjects: 0
Study: 20127732

Group type: EXPERIMENTAL
Intervention: High-dose silybin-phytosome (13 g daily for 14-31 days, mean 20 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 12
Study: 20127939

Group type: EXPERIMENTAL
Intervention: Percent body fat
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Percent adipose tissue
Number of subjects: 22
Study: 20128887

Group type: EXPERIMENTAL
Intervention: Combined strategy directed towards health-care professionals and patients including training on Clinical Practice Guidelines (CPG) and health education.
Number of subjects: 801

Group type: COMPARATOR
Intervention: Standard clinical practice (control group).
Number of subjects: 801
Study: 20129546

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stents (ZES)
Number of subjects: 436

Group type: COMPARATOR
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 436
Study: 20129549

Group type: EXPERIMENTAL
Intervention: Endeavor zotarolimus-eluting stent (ZES)
Number of subjects: 8314
Study: 20129551

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent (ZES) implantation
Number of subjects: 30
Study: 20129555

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 1580

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 1580

Group type: EXPERIMENTAL
Intervention: Post-intervention minimum stent area (MSA) for PES
Number of subjects: 1580

Group type: COMPARATOR
Intervention: Post-intervention minimum stent area (MSA) for BMS
Number of subjects: 1580

Group type: EXPERIMENTAL
Intervention: Post-intervention IVUS MSA
Number of subjects: 1580
Study: 20130244

Group type: EXPERIMENTAL
Intervention: SC-EPOCH-RR
Number of subjects: 33
Study: 20131111

Group type: EXPERIMENTAL
Intervention: STEMI alarm activated by prehospital emergency physicians
Number of subjects: 196

Group type: COMPARATOR
Intervention: No intervention (before implementation of the STEMI alarm)
Number of subjects: 196
Study: 20133268

Group type: EXPERIMENTAL
Intervention: Once-daily efavirenz 600 mg and lamivudine 300 mg with enteric-coated didanosine 400 mg (DART I)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Once-daily efavirenz 600 mg and lamivudine 300 mg with extended-release stavudine 100 mg (DART II)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Once-daily efavirenz-based antiretroviral therapy
Number of subjects: 0
Study: 20133465

Group type: EXPERIMENTAL
Intervention: Estrogen administration after GnRH antagonist and graded doses of GnRH
Number of subjects: 16
Study: 20133895

Group type: EXPERIMENTAL
Intervention: Dacetuzumab (SGN-40), 4 mg/kg and 12 mg/kg/week
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Dacetuzumab (SGN-40), 12 mg/kg/week
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Dacetuzumab (SGN-40) with steroid pre-medication
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Dacetuzumab (SGN-40)
Number of subjects: 44
Study: 20136164

Group type: EXPERIMENTAL
Intervention: Fenofibric acid + low-dose statin
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: Fenofibric acid + moderate-dose statin
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: Fenofibric acid + low- or moderate-dose statin
Number of subjects: 586

Group type: COMPARATOR
Intervention: Control: Low-dose statin monotherapy
Number of subjects: 586

Group type: COMPARATOR
Intervention: Control: Moderate-dose statin monotherapy
Number of subjects: 586
Study: 20139093

Group type: EXPERIMENTAL
Intervention: CRLF2 rearrangements
Number of subjects: 207

Group type: COMPARATOR
Intervention: No CRLF2 rearrangements
Number of subjects: 207
Study: 20139439

Group type: EXPERIMENTAL
Intervention: PCWP (pulmonary capillary wedge pressure)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: LA volume (left atrial volume)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: E/e' (Doppler index for LV filling)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curve analysis for PCWP, LA volume index, and E/e'
Number of subjects: 29
Study: 20139774

Group type: EXPERIMENTAL
Intervention: 150 mg/m cyclophosphamide
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 250 mg/m cyclophosphamide
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 350 mg/m cyclophosphamide
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Low-dose cyclophosphamide (150 and 250 mg/m)
Number of subjects: 13
Study: 20142198

Group type: EXPERIMENTAL
Intervention: Endeavor zotarolimus-eluting coronary stent
Number of subjects: 0

Group type: COMPARATOR
Intervention: Driver bare metal stent (BMS)
Number of subjects: 0
Study: 20142553

Group type: EXPERIMENTAL
Intervention: Intravitreous ranibizumab (lucentis)
Number of subjects: 0
Study: 20142724

Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg plus gefitinib 250 mg
Number of subjects: 42
Study: 20145390

Group type: EXPERIMENTAL
Intervention: Chronic-stage ischemic stroke patients
Number of subjects: 2069

Group type: EXPERIMENTAL
Intervention: Age, modified Rankin Scale (mRS), duration after onset, Japan Stroke Scale Depression score (JSS-D)
Number of subjects: 2069

Group type: EXPERIMENTAL
Intervention: Negative factors for PCS
Number of subjects: 2069

Group type: EXPERIMENTAL
Intervention: Negative factors for MCS
Number of subjects: 2069
Study: 20145731

Group type: EXPERIMENTAL
Intervention: Exercise intervention (150, 200, or 300 minutes/week)
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 397

Group type: COMPARATOR
Intervention: Control group (no prescribed exercise)
Number of subjects: 397
Study: 20147717

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiation therapy (42.5 Gy in 16 fractions over 22 days)
Number of subjects: 1234

Group type: COMPARATOR
Intervention: Standard radiation therapy (50.0 Gy in 25 fractions over 35 days)
Number of subjects: 1234
Study: 20149262

Group type: EXPERIMENTAL
Intervention: Maintenance Sorafenib (400 mg, p.o., twice a day for 12 months)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Combined therapy of 3DCRT/IMRT and TACE
Number of subjects: 30

Group type: COMPARATOR
Intervention: TACE combined with radiotherapy
Number of subjects: 30
Study: 20149736

Group type: EXPERIMENTAL
Intervention: Denosumab 120 mg subcutaneously monthly (every 28 days), with loading doses on days 8 and 15 of month 1.
Number of subjects: 37
Study: 20150292

Group type: EXPERIMENTAL
Intervention: MD-Logic Artificial Pancreas (MDLAP) System
Number of subjects: 7
Study: 20150297

Group type: EXPERIMENTAL
Intervention: Former intensive insulin treatment
Number of subjects: 1186

Group type: COMPARATOR
Intervention: Former conventional insulin treatment
Number of subjects: 1186
Study: 20151726

Group type: EXPERIMENTAL
Intervention: High-dose IV esomeprazole (80 mg infusion over 30 min, then 8 mg/hour for 71.5 hours)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-IV esomeprazole treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose IV esomeprazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-IV esomeprazole
Number of subjects: 0
Study: 20152220

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) with Angiotensin-Converting Enzyme Inhibitors (ACEIs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) with Angiotensin Receptor Blockers (ARBs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) with ACEI or ARB
Number of subjects: 0
Study: 20153880

Group type: EXPERIMENTAL
Intervention: Graduated elastic compression stockings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prophylactic Low Molecular Weight Heparin (LMWH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjusted-dose of LMWH through pregnancy and postpartum
Number of subjects: 0
Study: 20154700

Group type: EXPERIMENTAL
Intervention: Vasectomy by epithelial curettage with Vas-X
Number of subjects: 12
Study: 20155590

Group type: EXPERIMENTAL
Intervention: At-home unattended polysomnography
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Urine toxicology on polysomnographic nights
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Polysomnography signal quality and overall study success rates
Number of subjects: 88
Study: 20156060

Group type: EXPERIMENTAL
Intervention: Raltegravir (4-week intensification)
Number of subjects: 10
Study: 20156608

Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency (RF) ablation of the PV antrum, parasympathetic ganglionated plexi, and ligament of Marshall
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Postoperative management (medical therapy)
Number of subjects: 50
Study: 20156960

Group type: EXPERIMENTAL
Intervention: MREG sites (Minority Recruitment Enhancement Grants)
Number of subjects: 602

Group type: COMPARATOR
Intervention: Comparison sites (nonawarded sites)
Number of subjects: 602
Study: 20157038

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 20157136

Group type: EXPERIMENTAL
Intervention: Anticoagulants (90.5% of patients received anticoagulants)
Number of subjects: 844

Group type: COMPARATOR
Intervention: No anticoagulants (control group not explicitly mentioned)
Number of subjects: 844
Study: 20157193

Group type: EXPERIMENTAL
Intervention: Observation, medical management, or bilateral adrenalectomy
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Patients with Cushing syndrome (CS)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Spontaneous resolution of Cushing syndrome
Number of subjects: 112
Study: 20160046

Group type: EXPERIMENTAL
Intervention: Famciclovir (individualized single doses based on body weight ranging from 25 to 175 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Famciclovir
Number of subjects: 18
Study: 20160160

Group type: EXPERIMENTAL
Intervention: AHA guideline risk stratification
Number of subjects: 161808
Study: 20160169

Group type: EXPERIMENTAL
Intervention: Implantable leadless cardiac monitor (ICM)
Number of subjects: 247
Study: 20163987

Group type: EXPERIMENTAL
Intervention: MTD gemcitabine (1000 mg/m² on days 1 and 8), metronomic capecitabine (500 mg/m² twice a day on days 1-14), and sorafenib (400 mg twice a day on days 1-21) for six cycles followed by sorafenib monotherapy if clinical benefit was maintained.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MTD gemcitabine, metronomic capecitabine, and sorafenib regimen.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Adverse events related to the treatment regimen.
Number of subjects: 40
Study: 20167848

Group type: EXPERIMENTAL
Intervention: Dendritic cell vaccination (50 x 10(6) mature dendritic cells pulsed with autologous tumor lysate and KLH)
Number of subjects: 10
Study: 20170786

Group type: EXPERIMENTAL
Intervention: Calcium score (CS) = 0
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: No calcium
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Totally occluded vessels
Number of subjects: 291
Study: 20172911

Group type: EXPERIMENTAL
Intervention: Modified Task Force Criteria for ARVC/D diagnosis
Number of subjects: 0
Study: 20172912

Group type: EXPERIMENTAL
Intervention: Modified Task Force Criteria for ARVC/D diagnosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emerging diagnostic modalities and genetic advances
Number of subjects: 0
Study: 20173748

Group type: EXPERIMENTAL
Intervention: FAM13A variants (specifically rs7671167)
Number of subjects: 2940

Group type: COMPARATOR
Intervention: Control group (1,380 controls)
Number of subjects: 2940

Group type: EXPERIMENTAL
Intervention: Replication in one case-control group (n = 1,006) and two family-based cohorts (n = 3,808)
Number of subjects: 2940
Study: 20174766

Group type: EXPERIMENTAL
Intervention: Bone marrow (BM)-derived mononuclear cells administered to patients with limb ischaemia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Autologous stem cell therapy for ischaemic peripheral disease
Number of subjects: 0
Study: 20176858

Group type: EXPERIMENTAL
Intervention: ACSL1 rs9997745 GG homozygotes
Number of subjects: 1754

Group type: COMPARATOR
Intervention: Low-fat diet (<35% energy) or high-PUFA diet (>5.5% energy)
Number of subjects: 1754
Study: 20176990

Group type: EXPERIMENTAL
Intervention: Physician-directed patient self-management of left atrial pressure
Number of subjects: 40
Study: 20178624

Group type: EXPERIMENTAL
Intervention: Patient-centered quality improvement interventions (communication skills training and care management focused on explanatory models, socio-cultural barriers, and treatment preferences)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Standard quality improvement interventions (academic detailing about depression guidelines and disease-oriented care management)
Number of subjects: 132
Study: 20178723

Group type: EXPERIMENTAL
Intervention: PFA-100 collagen/epinephrine (CEPI)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: PFA-100 collagen/adenosine diphosphate (CADP)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Post-biopsy hematoma formation on US
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Macroscopic hematuria
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Packed red blood (PRBC) transfusions
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: PRBC transfusions
Number of subjects: 56
Study: 20179285

Group type: EXPERIMENTAL
Intervention: Light transmittance aggregometry
Number of subjects: 1069

Group type: EXPERIMENTAL
Intervention: Verify Now
Number of subjects: 1069

Group type: EXPERIMENTAL
Intervention: Platelet works
Number of subjects: 1069

Group type: EXPERIMENTAL
Intervention: Innovance PFA P2Y
Number of subjects: 1069

Group type: EXPERIMENTAL
Intervention: IMPACT-R
Number of subjects: 1069

Group type: EXPERIMENTAL
Intervention: Siemens PFA Collagen/ADP
Number of subjects: 1069
Study: 20179614

Group type: EXPERIMENTAL
Intervention: Conventional laboratory upper limit of normal (ULN) criteria
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Modified ALT ULN criteria
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 45
Study: 20180156

Group type: EXPERIMENTAL
Intervention: Focus groups on lifestyle modification and disease management
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Focus groups on management and education for diabetes and hypertension
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Interactive discussion groups
Number of subjects: 34
Study: 20180805

Group type: EXPERIMENTAL
Intervention: Axitinib 5 mg single dose followed by continuous 5 mg twice-daily dosing
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Axitinib 5 mg twice-daily
Number of subjects: 12
Study: 20181032

Group type: EXPERIMENTAL
Intervention: Intensive implementation strategy (education and tools for risk calculation, interpretation, and communication; patient decision aids)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Common implementation strategy (dissemination of the guideline)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Intensive implementation strategy
Number of subjects: 18

Group type: COMPARATOR
Intervention: Common implementation strategy
Number of subjects: 18
Study: 20181120

Group type: EXPERIMENTAL
Intervention: Single-session early psychological intervention
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 99
Study: 20181282

Group type: EXPERIMENTAL
Intervention: Latanoprost once daily (evening)
Number of subjects: 572
Study: 20182862

Group type: EXPERIMENTAL
Intervention: Fasting Plasma Glucose (FPG)
Number of subjects: 6006

Group type: EXPERIMENTAL
Intervention: HbA(1c)
Number of subjects: 6006

Group type: EXPERIMENTAL
Intervention: 2h post-OGTT Plasma Glucose (2hPG)
Number of subjects: 6006

Group type: EXPERIMENTAL
Intervention: High-risk HbA(1c) criteria (6.0-6.5%)
Number of subjects: 6006

Group type: COMPARATOR
Intervention: OGTT
Number of subjects: 6006

Group type: EXPERIMENTAL
Intervention: FPG and HbA(1c) levels
Number of subjects: 6006
Study: 20184584

Group type: EXPERIMENTAL
Intervention: Surgical excision for anal margin carcinomas
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Combined chemoradiotherapy for anal canal carcinomas
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: High-grade AIN progression to invasive cancer
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: HPV analysis in anal carcinoma
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: HPV analysis in anal margin carcinoma
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: HPV analysis in anal swabs
Number of subjects: 446
Study: 20184783

Group type: EXPERIMENTAL
Intervention: Sibutramine 10 mg once daily for 6 weeks
Number of subjects: 10742
Study: 20184807

Group type: EXPERIMENTAL
Intervention: Antipsychotic-naive first-episode schizophrenia patients
Number of subjects: 38

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 38
Study: 20186499

Group type: EXPERIMENTAL
Intervention: Stand-alone e-prescribing system with clinical decision support
Number of subjects: 30

Group type: COMPARATOR
Intervention: Paper-based prescribing (control)
Number of subjects: 30
Study: 20187924

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 to 60 mg; mean dose = 45.8 mg/day; SD = 15.1) for 52 weeks
Number of subjects: 570

Group type: COMPARATOR
Intervention: Placebo for 52 weeks
Number of subjects: 570
Study: 20188071

Group type: EXPERIMENTAL
Intervention: Serum miR-146a
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Serum miR-223
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: IL-6
Number of subjects: 100
Study: 20188202

Group type: EXPERIMENTAL
Intervention: NK cell-enriched donor lymphocyte infusions (DLIs)
Number of subjects: 30
Study: 20188503

Group type: EXPERIMENTAL
Intervention: Transfemoral aortic valve implantation (TAVI) using the CoreValve prosthesis.
Number of subjects: 30
Study: 20188504

Group type: EXPERIMENTAL
Intervention: Iodine-123 meta-iodobenzylguanidine ((123)I-mIBG) imaging with heart/mediastinum uptake ratio (H/M)
Number of subjects: 961

Group type: EXPERIMENTAL
Intervention: Iodine-123 meta-iodobenzylguanidine ((123)I-mIBG) imaging
Number of subjects: 961
Study: 20189159

Group type: EXPERIMENTAL
Intervention: 1% mecamylamine topically twice daily for 12 weeks
Number of subjects: 23
Study: 20189513

Group type: EXPERIMENTAL
Intervention: Third Eye Retroscope (TER)
Number of subjects: 298
Study: 20189674

Group type: EXPERIMENTAL
Intervention: PEG-IFN alfa-2b plus RBV
Number of subjects: 70
Study: 20190585

Group type: EXPERIMENTAL
Intervention: Enhanced vaccine education intervention with pictures and application vignettes and enhanced risk-reduction counseling (3 one-on-one counseling sessions)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Standard conditions
Number of subjects: 311
Study: 20190673

Group type: EXPERIMENTAL
Intervention: Tdap vaccination (Boostrix GlaxoSmithKline)
Number of subjects: 13427
Study: 20191490

Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Self-management
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Combined program
Number of subjects: 273
Study: 20191499

Group type: EXPERIMENTAL
Intervention: DHEA substitution (50 mg/day)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 20191935

Group type: EXPERIMENTAL
Intervention: Gaboxadol 15 mg
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Gaboxadol 10 mg
Number of subjects: 310

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study: 20194481

Group type: EXPERIMENTAL
Intervention: Citalopram treatment
Number of subjects: 1953
Study: 20194866

Group type: EXPERIMENTAL
Intervention: Ofatumumab (300 mg for dose 1; 2000 mg for doses 2 to 12) administered as eight weekly infusions followed by four monthly infusions over 24 weeks
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Ofatumumab
Number of subjects: 138
Study: 20197513

Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound (IVUS) assessment
Number of subjects: 140
Study: 20200024

Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg daily on 4-week cycles
Number of subjects: 35
Study: 20202270

Group type: EXPERIMENTAL
Intervention: Falls (1+ falls)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Multiple falls
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Fallers (1+ falls)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Health service costs
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Specific health services
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Risk factors for falls
Number of subjects: 109
Study: 20203173

Group type: EXPERIMENTAL
Intervention: Sunitinib (SU) 37.5 mg daily
Number of subjects: 45